BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 15831444)

  • 1. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
    Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacological activity of inhalation exposure to marijuana smoke in mice.
    Lichtman AH; Poklis JL; Poklis A; Wilson DM; Martin BR
    Drug Alcohol Depend; 2001 Jul; 63(2):107-16. PubMed ID: 11376914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between THC and cannabidiol in mouse models of cannabinoid activity.
    Varvel SA; Wiley JL; Yang R; Bridgen DT; Long K; Lichtman AH; Martin BR
    Psychopharmacology (Berl); 2006 Jun; 186(2):226-34. PubMed ID: 16572263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR; Koek W
    Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological evaluation of aerosolized cannabinoids in mice.
    Lichtman AH; Peart J; Poklis JL; Bridgen DT; Razdan RK; Wilson DM; Poklis A; Meng Y; Byron PR; Martin BR
    Eur J Pharmacol; 2000 Jul; 399(2-3):141-9. PubMed ID: 10884513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
    Welch SP; Huffman JW; Lowe J
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
    J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
    DeLong GT; Wolf CE; Poklis A; Lichtman AH
    Drug Alcohol Depend; 2010 Nov; 112(1-2):126-33. PubMed ID: 20619971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment.
    Wu X; French ED
    Neuropharmacology; 2000 Jan; 39(3):391-8. PubMed ID: 10698005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.
    Zimmer A; Zimmer AM; Hohmann AG; Herkenham M; Bonner TI
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5780-5. PubMed ID: 10318961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.
    Wiley JL; Marusich JA; Lefever TW; Antonazzo KR; Wallgren MT; Cortes RA; Patel PR; Grabenauer M; Moore KN; Thomas BF
    J Pharmacol Exp Ther; 2015 Sep; 354(3):328-39. PubMed ID: 26105953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Explication of CB
    Nguyen JD; Creehan KM; Grant Y; Vandewater SA; Kerr TM; Taffe MA
    Drug Alcohol Depend; 2020 Sep; 214():108166. PubMed ID: 32717503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action.
    Ko MC; Woods JH
    Psychopharmacology (Berl); 1999 Apr; 143(3):322-6. PubMed ID: 10353438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabimimetic properties of ajulemic acid.
    Vann RE; Cook CD; Martin BR; Wiley JL
    J Pharmacol Exp Ther; 2007 Feb; 320(2):678-86. PubMed ID: 17105826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
    Dhawan K; Kumar S; Sharma A
    J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiochemical and pharmacological characterization of a Delta(9)-THC aerosol generated by a metered dose inhaler.
    Wilson DM; Peart J; Martin BR; Bridgen DT; Byron PR; Lichtman AH
    Drug Alcohol Depend; 2002 Aug; 67(3):259-67. PubMed ID: 12127197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.
    Wiley JL; Marusich JA; Lefever TW; Grabenauer M; Moore KN; Thomas BF
    Neuropharmacology; 2013 Dec; 75():145-54. PubMed ID: 23916483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys.
    McMahon LR; Amin MR; France CP
    Behav Pharmacol; 2005 Sep; 16(5-6):363-72. PubMed ID: 16148440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.